2022
Sex‐ and strain‐specific effects of mitochondrial uncoupling on age‐related metabolic diseases in high‐fat diet‐fed mice
Goedeke L, Murt KN, Di Francesco A, Camporez JP, Nasiri AR, Wang Y, Zhang X, Cline GW, de Cabo R, Shulman GI. Sex‐ and strain‐specific effects of mitochondrial uncoupling on age‐related metabolic diseases in high‐fat diet‐fed mice. Aging Cell 2022, 21: e13539. PMID: 35088525, PMCID: PMC8844126, DOI: 10.1111/acel.13539.Peer-Reviewed Original ResearchConceptsControlled-release mitochondrial protonophoreAge-related metabolic diseasesHepatocellular carcinomaMetabolic diseasesHigh-fat diet-fed miceProtein kinase C epsilon activationDiet-induced obese miceWhole-body energy expenditureC57BL/6J male miceDiet-fed miceHigh-fat dietHepatic lipid peroxidationHepatic lipid contentMitochondrial uncouplingHepatic insulin resistanceHigh therapeutic indexHepatic mitochondrial biogenesisStrain-specific effectsSex-specific mannerCRMP treatmentHFD feedingUnwanted side effectsObese miceInsulin resistanceChronic ingestion
2021
Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS).
Gupta A, Nshuti L, Grewal U, Sedhom R, Parsons H, Blaes A, Virnig B, Lustberg M, Subbiah I, Nipp R, Dy S, Dusetzina S. Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS). Journal Of Clinical Oncology 2021, 39: 55-55. DOI: 10.1200/jco.2020.39.28_suppl.55.Peer-Reviewed Original ResearchPrescription drug coverageAnorexia/cachexia syndromeDrug coveragePocket costsRisk/benefit ratioPatient-clinician discussionsSupportive care guidelinesFinancial burdenList of drugsCost of drugsUse of drugsHigh financial burdenEnd of lifeCachexia syndromeCare guidelinesUnwanted side effectsGeneric olanzapineSide effectsClinical practiceCertain drugsMultiple drugsStudy authorsBenefit ratioDrugsLimited benefit
2020
The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
Lundsten S, Spiegelberg D, Raval NR, Nestor M. The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 980-990. PMID: 31912256, PMCID: PMC7075859, DOI: 10.1007/s00259-019-04673-1.Peer-Reviewed Original ResearchConceptsComplete remissionToxicity profileNeuroendocrine tumorsSomatostatin receptorsCombination treatmentHistological analysisFavorable toxicity profileBetter therapeutic resultsDose-limiting organHeat shock protein 90 inhibitorShock protein 90 inhibitorsNeuroendocrine tumor xenograftsMonotherapy groupGlomerular injuryUnwanted side effectsCombination groupTherapeutic resultsTherapeutic effectTumor xenograftsSide effectsTumor uptakeRemissionXenograftsTumorsHSP70 upregulation
2016
Selective antitumor activity of roscovitine in head and neck cancer
Gary C, Hajek M, Biktasova A, Bellinger G, Yarbrough WG, Issaeva N. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget 2016, 7: 38598-38611. PMID: 27233076, PMCID: PMC5122414, DOI: 10.18632/oncotarget.9560.Peer-Reviewed Original ResearchConceptsNeck cancerSide effectsGrowth of HPVHPV-negative tissuesHPV-positive headCancer cellsHuman papilloma virusTargeted therapeutic optionsDetectable side effectsNeck cancer cellsNormal cellsDNA damageRoscovitine administrationHPV positivityCyclin-dependent kinase inhibitorTherapeutic optionsUnwanted side effectsPapilloma virusCdk-7Xenografted tumorsP53-dependent cell deathSignificant DNA damageSelective antitumor activitySensitivity of cellsKinase inhibitors
2014
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro C, Lustberg M. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2014, 23: 2019-2024. PMID: 25519756, PMCID: PMC4804339, DOI: 10.1007/s00520-014-2556-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDexamethasoneDiphenhydramineDrug Administration ScheduleDrug HypersensitivityFamotidineFemaleHumansInfusions, IntravenousMiddle AgedNeoplasm StagingPaclitaxelPremedicationProspective StudiesRetrospective StudiesConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyRescue medication useBreast cancer patientsHypersensitivity reactionsPaclitaxel dosesRescue medicationMedication useSecond doseCancer patientsBreast cancerLife-threatening complicationsMajority of patientsDoses of paclitaxelProspective pilot trialUse of paclitaxelBreast cancer treatmentPrimary endpointInfusion reactionsPremedication regimenSubsequent dosesUnwanted side effectsResultsIn totalPilot trialStudy populationQuantitative Evaluation and Optimization of Co-drugging to Improve Anti-HIV Latency Therapy
Wong VC, Fong LE, Adams NM, Xue Q, Dey SS, Miller-Jensen K. Quantitative Evaluation and Optimization of Co-drugging to Improve Anti-HIV Latency Therapy. Cellular And Molecular Bioengineering 2014, 7: 320-333. PMID: 26191086, PMCID: PMC4501041, DOI: 10.1007/s12195-014-0336-9.Peer-Reviewed Original ResearchLatency-reversing agentsLatent infectionSingle drugPrimary T-cell modelLatent cellular reservoirsActivation thresholdHistone deacetylase inhibitorsT cell modelLatent HIVUnwanted side effectsInfected patientsCellular reservoirsDrug interactionsTherapeutic strategiesSide effectsRepeat stimulationDeacetylase inhibitorsViral activationInfectionFurther studiesHIVViral integrationDrugsCell modelViral promoters
2011
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Dunlea L, Rettig A, Lustberg M, Phillips G, Shapiro C. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2011, 20: 1991-1997. PMID: 22089428, PMCID: PMC3411299, DOI: 10.1007/s00520-011-1303-9.Peer-Reviewed Original ResearchConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyHypersensitivity reactionsRescue medicationPaclitaxel dosesSecond doseDoses of paclitaxelBreast cancer patientsUse of paclitaxelPotential unwanted side effectsConclusionsIn patientsPrimary endpointSubsequent dosesUnwanted side effectsCancer patientsPremedicationSide effectsPatientsSolid tumorsDoses 3MedicationsChemotherapyDosesHypersensitivityDose
2010
Characterization of the Six1 homeobox gene in normal mammary gland morphogenesis
Coletta RD, McCoy EL, Burns V, Kawakami K, McManaman JL, Wysolmerski JJ, Ford HL. Characterization of the Six1 homeobox gene in normal mammary gland morphogenesis. BMC Developmental Biology 2010, 10: 4. PMID: 20074369, PMCID: PMC2823684, DOI: 10.1186/1471-213x-10-4.Peer-Reviewed Original ResearchConceptsNormal mammary gland developmentAdult mammary glandMammary gland developmentMammary glandMammary developmentBreast cancerMouse modelBreast tumorigenesisEmbryonic mammary glandPostnatal mammary developmentRag1-/- miceNormal mammary gland morphogenesisGland developmentTransgenic mouse modelBreast cancer initiationViable therapeutic targetIndependent mouse modelsAdult mouse mammary glandAnti-cancer therapyMammary stem cellsFamily membersMouse mammary glandUnwanted side effectsRole of Six1Invasive carcinoma
2009
Granulomatous bronchiolitis of Crohn’s disease successfully treated with inhaled budesonide
Trow TK, Morris DG, Miller CR, Homer RJ. Granulomatous bronchiolitis of Crohn’s disease successfully treated with inhaled budesonide. Thorax 2009, 64: 546. PMID: 19478123, DOI: 10.1136/thx.2008.107185.Peer-Reviewed Original Research
2004
Modulation of septo-hippocampal θ activity by GABAA receptors: an experimental and computational approach11Supplementary data associated with this article can be found at doi:10.1016/j.neuroscience.2004.03.043.
Hajós M, Hoffmann W, Orbán G, Kiss T, Érdi P. Modulation of septo-hippocampal θ activity by GABAA receptors: an experimental and computational approach11Supplementary data associated with this article can be found at doi:10.1016/j.neuroscience.2004.03.043. Neuroscience 2004, 126: 599-610. PMID: 15183510, DOI: 10.1016/j.neuroscience.2004.03.043.Peer-Reviewed Original ResearchConceptsGABAA receptorsMedial septum/diagonal bandExtracellular single-unit recordingsPositive allosteric modulator diazepamTheta activitySepto-hippocampal activityTypes of neuronsSingle-unit recordingsSepto-hippocampal systemTheta oscillationsSepto-hippocampal circuitryEEG theta activitySeptal neuronsUnwanted side effectsSystemic administrationDiagonal bandAnesthetized ratsGABAA transmissionTheta frequency oscillationsPharmacological modulationSide effectsUnit recordingsAnxiolytic drugsPharmacological toolsCognitive function
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply